Japanese guidance for use of biologics for psoriasis (the 2019 version)-Reference-Cited by-同舟云学术

Japanese guidance for use of biologics for psoriasis (the 2019 version)

Published:2020-01-08 Issue:3 Volume:47 Page:201-222
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Saeki Hidehisa¹^ORCID,Terui Tadashi²,Morita Akimichi³^ORCID,Sano Shigetoshi⁴^ORCID,Imafuku Shinichi⁵^ORCID,Asahina Akihiko⁶^ORCID,Komine Mayumi⁷^ORCID,Etoh Takafumi⁸,Igarashi Atsuyuki⁹,Torii Hideshi¹⁰,Abe Masatoshi¹¹^ORCID,Nakagawa Hidemi⁶,Watanabe Akira¹²,Yotsuyanagi Hiroshi¹³,Ohtsuki Mamitaro⁷,

Affiliation:

1. Department of Dermatology Nippon Medical School Tokyo Japan

2. Department of Dermatology Nihon University School of Medicine Tokyo Japan

3. Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

4. Department of Dermatology Kochi Medical School Kochi University Kochi Japan

5. Department of Dermatology Faculty of Medicine Fukuoka University Fukuoka Japan

6. Department of Dermatology The Jikei University School of Medicine Tokyo Japan

7. Department of Dermatology Jichi Medical University Shimotsuke Japan

8. Division of Dermatology Tokyo Postal Services Agency Hospital Tokyo Japan

9. Division of Dermatology NTT Medical Center Tokyo Tokyo Japan

10. Division of Dermatology Tokyo Yamate Medical Center Tokyo Japan

11. Kojinkai Sapporo Skin Clinic Sapporo Japan

12. Research Division for Development of Anti‐Infective Agents Faculty of Medical Science and Welfare Tohoku Bunka Gakuen University Sendai Japan

13. Division of Infectious Diseases Advanced Clinical Research Center Institute of Medical Science The University of Tokyo Tokyo Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.15196

Reference89 articles.

1. The guideline and safety manual for use of anti‐TNF‐α agents in psoriasis;Ohtsuki M;Jpn J Dermatol,2010

2. Guideline and safety manual for use of biologic agents in psoriasis (the 2011 version);Ohtsuki M;Jpn J Dermatol,2011

3. Japanese guidance for use of biologics for psoriasis (the 2013 version)

4. Precautions for use of secukinumab. Website of the Japanese Dermatological Association.

5. For use of infliximab BS. Website of the Japanese Dermatological Association.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indian expert Delphi consensus on the diagnosis and management of flares of generalised pustular psoriasis;Indian Journal of Dermatology, Venereology and Leprology;2024-09-07

2. Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis;Journal of the American Academy of Dermatology;2024-08

3. Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study;Clinical, Cosmetic and Investigational Dermatology;2024-06

4. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan;Journal of Dermatological Treatment;2024-02-05

5. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial;The Journal of Dermatology;2024-01-24